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Abstract
Background—Optimal administration of transarterial chemoembolization (TACE), the standard 
approach for intermediate stage hepatocellular carcinoma (HCC), requires clinical and technical 
expertise. We sought to evaluate if TACE retains its effectiveness when administered across a 
broad range of healthcare settings. With increasing use of yttrium90 radioembolization (Y90), we 
explored the effectiveness of Y90 compared with TACE.
Methods—HCC patients diagnosed from 2004–2009 treated initially with TACE or Y90 were 
identified from the Surveillance Epidemiology and End-Results (SEER)-Medicare linkage. Key 
covariates included prediagnosis AFP screening, complications of cirrhosis, and tumor extent. 
Effect of treatment, patient, and healthcare system factors on overall survival (OS) was evaluated 
using multivariable Cox proportional hazards. Stratified OS estimates are provided. Propensity 
score (PS) weighting was used to compare effectiveness of Y90 to TACE.
Results—Of 1,528 with intra-arterial embolization, 577 had documentation of concurrent 
chemotherapy (e.g. TACE). Median OS was 21 months (95% CI 18–23) following TACE, 9 
months (95% CI 1–41) following Y90. Refined survival estimates stratified by stage, AFP 
screening, and liver comorbidity are presented. Ninety day mortality after TACE was 21–25% in 
patients with extrahepatic spread or vascular invasion. In the PS-weighted analysis, Y90 was 
associated with inferior survival, aHR 1.39 (95% CI 1.02–1.90).
Conclusions—The effectiveness of TACE is generalizable to Medicare patients receiving care in 
a variety of treatment settings. However, early post-treatment mortality is high in patients with 
advanced disease. We found no evidence for improved outcomes with Y90 compared with TACE. 
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Survival estimates from this large cohort can be used to provide prognostic information to patients 
considering palliative TACE.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of a handful of malignancies with rising incidence 
and mortality rates in the United States.[1, 2] HCC carries a very poor prognosis, in large 
part because two thirds of patients have underlying cirrhosis and most have multifocal 
cancer, both of which limit treatment options.[2, 3] Two intra-arterially delivered 
locoregional therapy (LRT) options are considered to be reasonable initial therapy for 
patients with unresectable HCC and compensated cirrhosis: transarterial chemoembolization 
(TACE) and yttrium90 radioembolization (Y90). TACE delivers chemotherapy directly to the 
cancer through the hepatic arterial system with subsequent arterial embolization, or by the 
contemporary approach of concurrent chemotherapy delivery and embolization in the form 
of doxorubicin-eluting beads. Among patients with nonmetastatic HCC and compensated 
cirrhosis, TACE improves survival over supportive care[4–6] and is widely considered the 
first-line treatment option.[7] . Bland embolization performed without chemotherapy is used 
for patients with less compensated cirrhosis at some centers to minimize the risk of the 
procedure. Bland embolization appears to offer less robust survival benefit.[4]
The optimal delivery of TACE requires considerable clinical expertise to appropriately select 
patients for therapy and technical expertise for safe and effective administration.[8] 
Therefore TACE effectiveness might be diminished in centers without ready access to 
multidisciplinary clinical teams including expert diagnostic and interventional radiology, 
hepatology, transplant surgery, and oncology. In a prior evaluation of HCC treatment and 
outcomes using the Surveillance Epidemiology and End Results (SEER) Medicare linkage 
of patients treated in the 1990s, outcomes following TACE were quite poor with a median 
survival of less than a year.[9] A more recent SEER-Medicare analysis of patients treated 
from 2000–2005 also showed a short median survival, only 14 months.[10] Both of these 
estimates were well below the quality metric of 20 months proposed by the Society of 
Interventional Radiology Standards of Practice Committee.[8] However, as the more 
contemporary analysis excluded patients who underwent ablation, resection, or transplant at 
any time, only patients with the most advanced disease were evaluated. Therefore, we sought 
to evaluate the effectiveness of first-line TACE across the spectrum of cancer stages in a 
contemporary cohort.
Y90-radioembolization, in which either glass or resin microspheres laden with yttrium90 are 
delivered to cancers through the hepatic arteries, is emerging as an excellent TACE 
alternative as data emerge reporting survival following Y90 to be comparable to TACE.[11–
21] With overlapping clinical indications and similar outcomes, both TACE and Y90 are 
reasonable initial therapy choices for HCC in a patient with compensated cirrhosis. 
However, the comparative effectiveness of these procedures as they are being administered 
throughout the United States is unknown. Therefore using this large observational dataset, 
we also sought to explore the comparative effectiveness of Y90 versus TACE.
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PATIENTS and METHODS
Study Population
The cohort was derived from the Surveillance Epidemiology and End Results (SEER) 
Medicare linkage (described in detail elsewhere[22, 23]). We included patients diagnosed 
with HCC from 2004 to 2009, excluding autopsy diagnoses. To avoid misclassification of 
liver metastases, patients with prior invasive cancer within 5 years were excluded.[9] To 
ensure availability of claims, only patients with continuous enrollment in Medicare A and B 
and patients not enrolled in Medicare Managed Care in the 12 months before and after 
diagnosis (or death) were included. This analysis was deemed exempt from review by the 
Office of Human Research Ethics at the University of North Carolina (#12-1828).
Covariates
Sociodemographic patient data, tumor size and number and presence of macrovascular 
invasion were obtained from SEER (see Supplemental Methods). Laboratory parameters 
were not available, therefore diagnosis codes for complications of cirrhosis were used to 
control for confounding liver disease.[24] HCC screening behavior was ascertained by pre-
diagnosis AFP[25, 26] as a surrogate measure of performance status as use of cancer 
screening is associated with decreased probability of frailty in cancer patients.[27] Cause of 
liver disease was ascertained from claims using ICD-9 diagnosis codes for hepatitis B virus, 
hepatitis C virus, alcoholic cirrhosis, and other cirrhosis. Non-cirrhotic comorbidity was 
determined using the Klabunde modification of the Charlson Comorbidity Index (CCI).[28] 
All claims-based covariates were ascertained in the 12 months before diagnosis.
Treating hospital was defined for the majority of patients from inpatient claims on the date 
of initial procedure. Hospital characteristics were derived from the SEER hospital file. 
Hospital volume was defined as LRT volume at the treating hospital in the 12 months 
preceding each individual patient’s treatment.
Treatment
Treatment group was determined by initial therapy delivered. Codes for arterial occlusion 
without intra-arterial radiotherapy were categorized as embolization (ETable 1); those with 
codes for chemotherapy or intra-arterial chemotherapy delivery at time of embolization were 
classified as chemoembolization (TACE) and those without as bland embolization (TAE). 
Because chemotherapy claims are reliable when present but are less well identified in 
records of hospitalized patients,[29] some patients receiving chemoembolization were likely 
misclassified as bland embolization. Because the intent of the procedure cannot be 
ascertained from claims, some patients classified as TAE may have received embolization 
for reasons other than anticancer therapy such as to control bleeding from a ruptured tumor 
or in preparation for Y90-radioembolization that was subsequently aborted. There is not a 
specific code for drug-eluting beads thus we could not compare specific TACE strategies. 
Patients with codes for intra-arterial radiotherapy delivery were categorized as receiving 
Y90regardless of embolization. Because pre-procedure arterial embolization is required to 
ensure dose and safety of Y90embolization codes in the 60 days before Y90 administration 
were considered part of Y90.
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Statistical Analysis
Overall survival (OS) was measured from date of initial procedure until death. Kaplan-Meier 
methods estimated OS for the entire cohort and within strata of tumor extent, liver 
comorbidity, and use of pre-diagnosis AFP screening. Cox proportional hazards (PH) 
models were used to evaluate factors associated with OS. Robust variances were used in all 
analyses.
As TACE is the standard treatment, we also sought to ask “what would the effect of Y90 be 
among patients typically treated with TACE” by comparing the effectiveness of Y90 to 
TACE in a population of patients resembling those selected for initial TAE/TACE. To do so, 
a weighted pseudo-population was created from the propensity score (PS) for TAE/TACE 
(see Supplemental Methods).[30] This created treatment groups balanced on key patient 
characteristics in which multivariable Cox PH models were used to adjust for residual 
covariate imbalances and OS was compared by treatment. In sensitivity analyses, we 
compared the effectiveness of Y90 to TAE/TACE after restricting to only those TACE 
patients with codes for chemotherapy. We also conducted a PS-trimming sensitivity analysis 
to address the potential for unmeasured confounding by frailty.[31] As patients treated 
contrary to prediction are most likely to have unmeasured confounding that influences 
treatment selection (e.g. frailty), omitting them may improve the validity of the treatment 
effect estimate. If the observed treatment effect were due to unmeasured confounding, it 
would be expected to approach the null with trimming. Because a larger proportion of TACE 
patients underwent subsequent curative surgery, sensitivity analysis explored the magnitude 
of this effect by censoring patients at the time of curative surgery.
RESULTS
Initial LRT was administered to 1,651 patients, including 1,528 treated with TAE/TACE and 
121 with first-line Y90 (Figure 1). Of TAE/TACE patients, 577 (38%) received TACE. 
Median age of the TAE/TACE group was 72 (range 27–94), 66% of whom were white and 
14% Asian (Table 1). The majority of TACE patients had liver-confined unifocal (207, 42%) 
or multifocal (207, 36%) disease without macrovascular invasion, though 126 (22%) had 
either macrovascular invasion or extrahepatic disease. Second-line therapy was administered 
to 1,010 (66%) TAE/TACE patients, including repeat TAE/TACE in 635 (42%), curative 
surgery in 99 (6%), ablation in 129 (8%), and drug therapy in 104 (7%) (ETable 2). Many 
second procedures likely represent planned contralateral treatment as 295 of 635 repeat 
TAE/TACEs occurred within 60 days of first treatment.
Survival After TACE
Median survival in TACE patients was 21 months (95% CI 18–23), ranging from 24 months 
(95% CI 21–28) in patients with solitary tumors without vascular invasion to 11 months 
(95% CI 5–20) in patients with multiple tumors and vascular invasion. Ninety day mortality 
was high in patients with extrahepatic spread (25%) or multiple tumors with vascular 
invasion (21%). Stratification by pre-diagnosis AFP screening and codes for liver 
comorbidity further refined these estimates (Table 2, Figure 2).
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Patient sex, race/ethnicity, census tract median income, non-liver comorbidity, and cause of 
liver disease were not associated with survival (Table 1). Patients born in Asia or other non-
US sites had significantly longer OS compared with US born patients—a possible surrogate 
for hepatitis B infection. Treatment at an NCI-designated Comprehensive Cancer Center and 
at a hospital with a solid organ transplant program was associated with significantly better 
OS.
Comparative Effectiveness
Median survival in Y90 patients was 9 months (95% CI 1–41). In the PS-weighted 
population balanced across key clinical covariates (ETable 2), Y90 was associated with an 
increased risk of death compared with TAE/TACE, adjusted HR 1.39 (95% CI 1.02–1.90). 
The effect was more pronounced when restricting just to TACE patients, adjusted HR 1.88 
(95% CI 1.40–2.53, ETable 3). We found little evidence that the greater risk of death with 
Y90 resulted from residual unmeasured confounding as trimming of patients treated contrary 
to prediction did not lead to an attenuation of the hazard ratio towards the null.
DISCUSSION
In this large cohort of patients with newly diagnosed HCC, the survival estimate of 21 
months for the true chemoembolization patients suggest TACE effectiveness is retained 
across the broad range of health system settings where Medicare beneficiaries are treated in 
the United States; though treatment at a center with a solid organ transplant program or NCI 
Comprehensive status was associated with the best outcomes. However, we found that in the 
subgroup of TACE-treated patients whose disease was more extensive than is typically 
considered TACE amenable (extrahepatic disease or multifocal disease with macrocascular 
invasion), immediate post-treatment mortality was very high with 21 to 25% of patients 
dying within 90 days of treatment.
The expected duration of survival following TACE varies widely as it is dependent upon 
both the extent of cancer and the degree of underlying cirrhosis.[32–34] In well done[35] 
randomized clinical trials using conventional (non-bead) TACE for unresectable HCC, 
median OS has been reported between 13.8–28.7 months.[4, 5, 36] Better outcomes have 
been reported recently in patients with well compensated cirrhosis using the contemporary 
approach of doxorubicin-eluting bead TACE.[37–39] Based on the existing data, the 
Standards of Practice Committee of the Society of Interventional Radiology has set the 
quality threshold of median survival following TACE at 20 months.[8] While we found the 
median survival among Medicare beneficiaries treated with initial TACE to meet this quality 
threshold, two prior population-based observational studies also using SEER-Medicare 
reported post-TACE median survivals of only <12 and 14 months.[9, 10] The first of these 
investigations was conducted in the 1990s when only 4% of patients were treated with 
TACE. As use and techniques of TACE have evolved since the 1990s, it is likely that 
survival has also improved over this time. The more recent investigation of HCC patients 
treated between 2000 and 2005 was designed to compare palliative approaches in the 
elderly; it intentionally excluded patients younger than 65 and those receiving subsequent 
curative therapies. In contrast we chose to retain younger patients eligible for Medicare on 
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the basis of disability to more broadly investigate the effectiveness of TACE in the United 
States. We also retained patients who underwent subsequent curative surgery, transplant and 
ablative procedures as excluding such patients underestimates TACE effect by selectively 
excluding those with the best response. Because of these differences we do not believe these 
data to be conflicting, rather, our report expands on this prior work by providing survival 
estimates across a broader range of treatment scenarios.
Because registry data do not contain laboratory data or performance status, we could not 
evaluate outcomes by HCC-relevant clinical categories of Child Pugh or BCLC stage. To 
address this limitation we used surrogates for the components of BCLC stage (extent of 
cancer, performance status, and Child Pugh score)[40] to refine our survival estimates. We 
used the cancer-specific tumor extent from SEER that includes macrovascular invasion. 
However, the predominantly clinical staging paradigm of HCC differs greatly from other 
cancers. Concordance between registrar-reported vascular invasion has not been evaluated to 
the best of our knowledge, but may be poor. Codes for complications of cirrhosis prior to 
diagnosis were used as a marker of the extent of cirrhosis. As this approach relies on the 
thoroughness of physician coding, these codes likely underestimate the extent of cirrhosis 
and limit the direct clinical applicability of the estimates provided for patients with and 
without liver comorbidity in this analysis. Pre-diagnosis AFP screening was chosen given 
prior evidence of cancer screening as a marker of frailty,[41] though AFP is likely a marker 
for multiple factors associated with improved outcomes including possible earlier detection 
with a lower burden of disease and engagement with the healthcare system. While these 
means of stratifying patients is less granular than validated HCC staging systems, each 
component was strongly associated with survival.
Fifteen percent of TACE-patients in this cohort had disease beyond that for which TACE is 
currently recommended,[7] including multifocal disease with macrovascular invasion and 
extrahepatic disease. In this subgroup of patients with advanced cancer, 90 day mortality 
was very high, 21–25%. Because untreated patients are inherently different, we did not 
compare outcomes between treated and untreated patients to explore the extent to which this 
early mortality was the result of hepatic decompensation following treatment or ineffective 
treatment in terminally ill individuals. In this sicker group of patients it would be 
particularly relevant to know more detail about the technical aspects of TACE, specifically 
whether the procedure was performed using super selective techniques that minimize the 
damage to non-neoplastic liver, or whether a more extensive embolization was performed. 
Unfortunately this quality metric cannot be ascertained from embolization codes in any 
reliable fashion. However, if indeed patients with poorly compensated cirrhosis were treated 
with less selective embolization this might account for the poor outcomes of TACE in this 
advanced disease group. But, without this information we cannot definitively conclude 
whether it is all TACE that does not benefit patients with advanced disease, or merely poor 
quality TACE.
Patients with a poor performance status, diffuse infiltrative cancer, Child-Pugh C cirrhosis, 
and Child Pugh B cirrhosis with portal vein thrombosis all have an exceptionally poor 
prognosis even with TACE or Y90.[11, 32, 33] Unfortunately, there are few data available to 
help determine whether LRT improves outcomes in this high risk group, or if they are better 
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served by sorafenib or supportive care. Studies designed to evaluate if TACE and/or Y90 
improve outcomes over supportive care or sorafenib such as NCT01887717 (Y90 versus 
sorafenib in patients with portal vein occlusion) are difficult to complete, but of paramount 
importance.
Our exploration of the comparative effectiveness of Y90-radioembolization to TACE was 
limited by a small number of Y90 treated patients; however we found no suggestion that Y90 
offered a survival advantage over TACE. The median survival of 9 months was well below 
what has been reported for patients with compensated cirrhosis following Y90-
radioembolization,[11, 12, 15, 21, 32] and may simply reflect use of Y90 in patients with 
more advanced liver disease and a larger burden of cancer.
Our study also shows that while registry-linked claims data allow for a broad overview of 
outcomes of HCC treatment, the lack of HCC-relevant staging—specifically laboratory 
parameters and components of Child Pugh score—markedly limits the feasibility of a 
nuanced study. As HCC is one of a few cancers with a rising incidence and mortality in the 
US,[42] efforts should be made to incorporate laboratory parameters relevant to HCC 
staging into mandatory cancer registry reporting. Such efforts would improve the ability to 
study the comparative safety and effectiveness of emerging therapies for this deadly disease.
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Figure 1. 
Cohort Assembly
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Figure 2. 
Kaplan-Meier Estimates of Survival Following Transarterial Chemoembolization. Survival 
estimates for patients with documented chemotherapy administration at time of TACE 
procedure for the entire cohort n=577 by tumor extent (A); and for single tumors without 
vascular invasion n=244 (B) and multiple tumors without vascular invasions n=207 (C) by 
AFP screening and liver comorbidity.
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Figure 3. 
Kaplan-Meier Estimates of Survival by Treatment. Survival estimates for TACE and 
yttrium90-radioembolization are shown for the propensity score weighted population.
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Table 1
Patient Characteristics and Association with Survival
Characteristic TACE + TAE
n=1525
TACE
n=577 (38%)
Multivariate HR,
95% CI
p-value
Treatment
   TACE, no chemo code - 1
   TACE, with chemo code 0.78, 0.69–0.89 <0.001
Median Age (range) 72 (27–94) 72 (27–94) - -
Age
   < 65 years 296 (19%) 108 (19%) 1
   65–74 years 635 (42%) 259 (45%) 1.02, 0.85–1.22 0.82
   75+ years 597 (39%) 210 (36%) 1.21, 1.00–1.46 0.06
Sex
   Male 1,045 (68%) 390 (68%) 1
   Female 483 (32%) 187 (32%) 1.03, 0.90–1.17 0.71
Race/Ethnicity
   White 1,008 (66%) 374 (65%) 1
   African American 136 (9%) 46 (8%) 0.94, 0.75–1.18 0.60
   Asian 213 (14%) 92 (16%) 0.88, 0.68–1.15 0.35
   Hispanic/Other 171 (11%) 65 (11%) 0.93, 0.75–1.15 0.48
Place of Birth
   USA 820 (54%) 278 (48%) 1
   Asia 203 (13%) 85 (15%) 0.67, 0.51–0.88 0.004
   Other/Missing^ 505 (33%) 214 (37%) 0.56, 0.49–0.65 <0.001
Hepatitis B* 147 (10%) 72 (12%) 0.89, 0.70–1.13 0.34
Hepatitis C* 529 (35%) 211 (37%) 1.08, 0.94–1.26 0.28
Alcohol* 182 (12%) 73 (13%) 0.99, 0.82–1.21 0.96
Other* 127 (8%) 51 (9%) 97, 0.77–1.22 0.78
Modified Charlson Score
   0 330 (22%) 111 (19%) 1
   1 440 (29%) 181 (31%) 1.01, 0.85–1.19 0.95
   2+ 758 (50%) 285 (49%) 1.06, 0.90–1.24 0.50
# of Cirrhosis Complications
   0 1161 (76%) 464 (80%) 1
   1 240 (16%) 78 (14%) 1.37, 1.16–1.62 <0.001
   2+ 127 (8%) 35 (6%) 1.51, 1.18–1.94 0.002
J Natl Compr Canc Netw. Author manuscript; available in PMC 2016 May 10.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Sanoff et al. Page 15
Characteristic TACE + TAE
n=1525
TACE
n=577 (38%)
Multivariate HR,
95% CI
p-value
# of Pre-Diagnosis AFP Claims
   0 639 (42%) 204 (35%) 1
   1 456 (30%) 176 (31%) 0.79, 0.69–0.92 0.002
   2+ 433 (28%) 197 (34%) 0.72, 0.61–0.85 <0.001
Extent of Tumor
   Single, no vascular invasion 639 (42%) 244 (42%) 1
   Multiple, no vascular invasion 503 (33%) 207 (36%) 1.34, 1.17–1.54 <0.001
   Single, vascular invasion 108 (7%) 38 (7%) 1.18, 0.93–1.52 0.17
   Multiple, vascular invasion 130 (8%) 48 (8%) 1.62, 1.30–2.01 <0.001
   Extrahepatic Extension or NOS 148 (10%) 40 (7%) 1.75, 1.40–2.19 <0.001
Maximum Tumor Size
   ≤3 cm 344 (23%) 150 (26%) 1
   3–5 cm 375 (25%) 151 (26%) 1.26, 1.5–1.51 0.02
   > 5 cm 568 (37%) 202 (35%) 1.81, 1.51–2.16 <0.001
   Unknown 241 (16%) 74 (13%) 1.70, 1.36–2.13 <0.001
Teaching Hospital+ 1,339 (88%) 508 (89%) 1.06, 0.87–1.30 0.55
Hospital NCI Designation in 2005
   None 1,202 (80%) 471 (82%) 1
   Clinical 36 (2%) 18 (3%) 1.18, 0.78–1.79 0.42
   Comprehensive 272 (18%) 84 (15%) 0.75, 0.63–0.89 <0.001
Hospital with Solid Organ Transplant 1,076 (71%) 422 (74%) 0.72, 0.62–0.85 <0.001
Hospital Volume in Prior 12 months
   <5 802 (52%) 258 (45%) 1
   5–20 420 (27%) 165 (29%) 0.92, 0.79–1.07 0.26
   >20 306(20%) 154 (27%) 0.88, 0.73–1.07 0.19
TACE, transarterial chemoembolization; AJCC, American Joint Commission on Cancer; NCI, National Cancer Institute; HR, Hazard Ratio. Notes: 
HR adjusted for variables shown and census track median income, SEER region.
^
n=360 missing place of birth and n=145 non-US non-Asian born.
*
Causes are not mutually exclusive. HR referent= no.
+
Because of missing data, hospital variables do not sum to 1528.
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